Table 3.
Clinical characteristics by initial vasopressor in patients receiving 1 vasopressor
| Patients with MAP data (n = 69) |
Patients with CPP data (n = 48) |
|||||
|---|---|---|---|---|---|---|
| phenylephrine (n = 43) | dopamine (n=19) | norepinephrine (n = 7) | phenylephrine (n = 35) | dopamine (n = 8) | norepinephrine (n = 5) | |
| Age1, years | 13 (1.1, 17) | 7 (0.1, 17) | 15 (2.9, 17) | 13 (1.1, 17) | 6 (2.4, 17) | 15 (2.9, 17) |
| Male | 67% | 74% | 86% | 69% | 88% | 80% |
| Head AIS score2 | 5 (5, 5) | 5 (4, 5) | 5 (5, 5) | 5 (4, 5) | 5 (4, 5) | 5 (5, 5) |
| ISS2 | 34 (25, 43) | 30 (26, 50) | 50 (30, 57) | 34 (25, 43) | 29.5 (23, 40.5) | 50 (30, 57) |
| GCS score at ICU admission2 | 5 (3, 7) | 4 (3, 7) | 6 (4, 8) | 5 (3, 7) | 3.5 (3, 6) | 5 (4, 8) |
| Blood products2,3, ml/kg | 7 (0, 25) | 8 (0, 20) | 0 (0, 0) | 0 (0, 17) | 3 (0, 9) | 0 (0, 0) |
| Fluid balance2,3, ml/kg | 18 (2, 49) | 18 (−30, 64) | 14 (6, 41) | 15 (−2, 44) | −19 (−34, 7) | 14 (6, 14) |
| LOS in survivors2, days | 18 (13, 25) | 13 (3.5, 20.5) | 28 (16, 41) | 17.5 (11, 24) | 20 (6, 21.5) | 25 (15, 47) |
| Time to pressor start2,4, h | 12 (3, 31) | 9 (3, 34) | 82 (6, 117) | 15 (4, 42) | 30.5 (6, 53.5) | 82 (46, 116) |
| In-hospital mortality | 33% | 37% | 14% | 24% | − | 20% |
| Polytrauma | 53% | 42% | 86% | 57% | 63% | 80% |
| Orthopedic5 | 83% | 63% | 100% | 80% | 80% | 100% |
| Abdominal5 | 26% | 63% | 50% | 30% | 60% | 50% |
| Thoracic5 | 57% | 50% | 83% | 55% | 20% | 75% |
| Multiple5 | 52% | 50% | 100% | 50% | 40% | 100% |
| Propofol6 | 42% | 16% | 43% | 49% | 25% | 60% |
| Hypertonic saline6 | 37% | 16% | 71% | 40% | 25% | 80% |
| Mannitol6 | 42% | 37% | 43% | 46% | 50% | 60% |
| Furosemide6 | 5% | 5% | − | 6% | − | − |
| Pentobarbital6 | 2% | 11% | − | 3% | 25% | − |
1
Median (min., max.).
2
Median (IQR).
3
Over 12 h (6 h before and 6 h after start of first vasopressor).
4
Time in hours to start of pressor after admission to ICU (negative values indicate start of medication prior to arrival in ICU, i.e. started in the emergency department).
5
Sites of extracranial trauma in the patients with polytrauma.
6
Administered anytime during the first 3 h after start of first vasopressor.